Observations placeholder

Zoledronic acid

 zoledronate (marketed by Novartis under the trade names Zometa  , Zomera, Aclasta and Reclast) is a bisphosphonate. Zometa is used to prevent skeletal fractures in patients with cancers such as multiple myeloma and prostate cancer, as well as for treating osteoporosis.  It can also be used to treat hypercalcemia of malignancy.

 Reclast is a single 5 mg infusion for the treatment of Paget's disease of bone. In 2007, the U.S. Food and Drug Administration (FDA) also approved Reclast for the treatment of postmenopausal osteoporosis.

Approvals and indications

In all cases administration is by intravenous infusion over a minimum of 15 minutes.

 Uses

• Bone complications of cancer - As Zometa (4 mg every 3 weeks) for bone complications of cancer.
• Osteoporosis - As Aclasta (5 mg infusion once per year) for treatment of osteoporosis in men and post-menopausal women at increased risk of fracture.
• Hypercalcemia of Malignancy - Zomera® (zoledronic acid for injection) is used for the treatment of hypercalcemia of malignancy.
• Multiple Myeloma and Bone Metastases of Solid Tumors - Zomera is used for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy.
• Pagets disease - As Reclast a single dose of 5 mg is used for the treatment of Paget's disease

Side effects

folow the link for the reports - 37,104 reports from FDA and social media of adverse side effects.

Side effects can include fatigue, anemia, muscle aches, fever, and/or swelling in the feet or legs. Flu-like symptoms are commonly experienced.  Zoledronate is processed via the kidneys; consequently its administration is not recommended for patients with reduced renal function or kidney disease. Some cases of acute renal failure requiring dialysis or having a fatal outcome, following Reclast use, have been reported to the US FDA.

A rare complication that has been recently observed in cancer patients being treated with bisphosphonates is osteonecrosis of the jaw.

Time on Zometa when people have Hallucination  :

On Mar, 18, 2015: 38,835 people reported to have side effects when taking Zometa. Among them, 3,125 people (8.05%) have Death.

Time on Zometa when people have Death  :